# Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

> **NCT01301612** · PHASE2 · WITHDRAWN · sponsor: **Eurofarma Laboratorios S.A.**

## Conditions studied

- Carcinoma
- Adenocarcinoma
- Uterine Cervix Adenosquamous Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Cisplatin
- **RADIATION:** Brachytherapy
- **DRUG:** Cisplatin
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT01301612
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-01
- **Primary completion:** 2017-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Regulatory requirement. A phase III study is being designed.
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01301612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01301612, "Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01301612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*